Skip to main content

Biogen Inc. (BIIB)

NASDAQ: BIIB · Delayed Price · USD
-1.20 (-0.44%)
After-hours:Oct 21, 2021 6:53 PM EDT
3.64 (1.37%)
At close: Oct 21, 4:00 PM
Market Cap40.32B
Revenue (ttm)11.10B
Net Income (ttm)1.55B
Shares Out148.00M
EPS (ttm)12.50
PE Ratio21.61
Forward PE13.26
Ex-Dividend Daten/a
Previous Close266.57
Day's Range266.29 - 271.94
52-Week Range223.25 - 468.55
Price Target370.56 (+37.1%)
Est. Earnings Daten/a

About BIIB

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treati...

IPO DateSep 16, 1991
CEOGeorge Scangos
Stock ExchangeNASDAQ
Ticker SymbolBIIB
Full Company Profile

Financial Performance

In 2020, Biogen's revenue was $13.44 billion, a decrease of -6.49% compared to the previous year's $14.38 billion. Earnings were $4.00 billion, a decrease of -32.06%.

Financial Statements

Analyst Forecast

According to 33 analysts, the average rating for Biogen stock is "Hold." The 12-month stock price forecast is 370.56, which is an increase of 37.14% from the latest price.

Price Target
(37.14% upside)
Analyst Consensus: Hold


Is it safe to buy Biogen stock after boosting guidance ahead of Street forecasts?

On Wednesday, Biogen Inc. (NASDAQ:BIIB) shares edged slightly higher after announcing its most recent quarterly results. The company reported better-than-expected fiscal Q3 revenue and earnings whilst a...

1 day ago - Invezz

Sage, Biogen Plan to File Zuranolone NDA for MDD in 2022

Sage (SAGE) and partner Biogen are looking to get approval for zuranolone as an oral treatment for major depressive disorder. They will start rolling submission of an NDA in early 2022 for the candidate.

1 day ago - Zacks Investment Research

Novavax shares tumble on COVID-19 vaccine concerns; Biogen beats q3 estimates

Yahoo Finance's Brian Sozzi, Brian Cheung and Julie Hyman break down how Novavax, Biogen, and Abbott Labs stocks for Wednesday October 20, 2021. Don't Miss: Valley of Hype: The Culture That Built Elizab...

Other symbols:NVAX
1 day ago - Yahoo Finance

Biogen (BIIB) Q3 Earnings Top, Aduhelm Sales Negligible

Biogen (BIIB) beats third-quarter estimates for both earnings and sales and ups its financial guidance for 2021.

1 day ago - Zacks Investment Research

Abbot Labs and Biogen Outshine Novavax in the Health Care Sector

Just before Tuesday's close, Netflix (NASDAQ: NFLX) reported better-than-expected earnings by adding 4.4 million subscribers in the third quarter. The company cited a robust slate of content including t...

Other symbols:ABT
1 day ago - Benzinga

Biogen Inc. (BIIB) Q3 Earnings and Revenues Surpass Estimates

Biogen Inc. (BIIB) delivered earnings and revenue surprises of 14.94% and 3.82%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

1 day ago - Zacks Investment Research

Will Biogen Stock Rise After The Recent 6% Fall?

The stock price of Biogen reached a 52-week high of $468 this June before a sell-off drove the stock price down over 40% to its current level of around $266. The stock decline was partly driven by pessi...

1 day ago - Forbes

Biogen Posts Just $300K Sales From Aduhelm In Q3, Though Earnings Beat Estimates

Biogen Inc (NASDAQ: BIIB) has posted Q3 adjusted EPS of $4.77 ahead of the consensus estimate of $4.11, but quarterly profit fell around 53% Y/Y to $329.2 million on the continued competition for Compan...

1 day ago - Benzinga

Stocks making the biggest moves before the bell: Biogen, Novavax, Netflix, Verizon & more

These are the stocks posting the largest moves before the bell.

Other symbols:NFLXNVAXVZ
1 day ago - CNBC

Biogen posts much smaller-than-expected sales of new Alzheimer's drug

Biogen Inc reported a much smaller-than-expected quarterly sales of its Alzheimer's drug Aduhelm on Wednesday, as the recently launched treatment faces sluggish uptake following scrutiny over its approv...

1 day ago - Reuters

Biogen sales face pressure from slow uptake of Alzhiemer's drug

Biogen Inc's Alzheimer's drug will be of little help to its third-quarter sales, Wall Street analysts said, as the drugmaker faces an uphill task of convincing hospitals and clinics to use the $56,000-a...

2 days ago - Reuters

Earnings Outlook For Biogen

Biogen(NASDAQ:BIIB) is set to give its latest quarterly earnings report on Wednesday, 2021-10-20. Here's what investors need to know before the announcement.

2 days ago - Benzinga

Sage Therapeutics and Biogen Announce Plans to Submit a New Drug Application (NDA) for Zuranolone to the U.S. Food & ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today announced their plan to submit a New Drug Application (NDA) to the U.S. Food and Drug Admin...

Other symbols:SAGE
2 days ago - Business Wire

Biogen's (BIIB) Tofersen Reports Mixed Data From ALS Study

Biogen's (BIIB) phase III study evaluating tofersen for ALS with SOD1 mutation fails to meet the primary endpoint of the study. However, the study shows signs of reduced disease progression with tofersen.

3 days ago - Zacks Investment Research

Biogen (BIIB) to Report Q3 Earnings: What's in the Cards?

Investor focus is likely to be on sales of new Alzheimer's drug, Aduhelm when Biogen (BIIB) reports third-quarter earnings.

3 days ago - Zacks Investment Research

Is Biogen stock a buy or sell as ALS study falls short of primary endpoints?

On Monday, Biogen Inc. (NASDAQ:BIIB) shares edged lower after announcing crucial data from the Phase 3 study for tofersen in patients with amyotrophic lateral sclerosis (ALS).  According to the data, th...

3 days ago - Invezz

Biogen's Antisense Candidate Flunks In Late-Stage Neurodegenerative Disorder Trial

Biogen Inc (NASDAQ: BIIB) has announced topline results from its Phase 3 VALOR study of tofersen (BIIB067), an investigational antisense drug for superoxide dismutase 1 (SOD1) amyotrophic lateral sclero...

3 days ago - Benzinga

Biogen Announces Topline Results from the Tofersen Phase 3 Study and its Open-Label Extension in SOD1-ALS

A Media Snippet accompanying this announcement is available by clicking on the image or link below:

4 days ago - GlobeNewsWire

3 Highly Profitable Stocks Wall Street Thinks Will Soar 39% or More

There are good reasons behind analysts' optimism about these stocks.

Other symbols:BMYVRTX
6 days ago - The Motley Fool

Topline Results from Tofersen Phase 3 Study and its Open Label Extension in SOD1-ALS to be Presented at the American ...

CAMBRIDGE, Mass., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced topline results from its pivotal Phase 3 VALOR study of tofersen (BIIB067), an investigational antisense ol...

1 week ago - GlobeNewsWire

Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for

Biogen Inc. (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 week ago - Zacks Investment Research

New Data at ECTRIMS 2021 Highlight Biogen's Focus on Patient-Centered Outcomes and Improving the MS Patient Experience

CAMBRIDGE, Mass., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced new data from its industry-leading portfolio of multiple sclerosis (MS) therapies. These data include addit...

1 week ago - GlobeNewsWire

New MS PATHS Data at ECTRIMS 2021 Confirm Biogen's Disease-Modifying Therapies Do Not Reduce Antibody Response to COV...

CAMBRIDGE, Mass., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced results of a new analysis of immune response to the COVID-19 vaccine among people with multiple sclerosis (...

1 week ago - GlobeNewsWire

Is Biogen stock a buy after Teva settled the Vumerity patent lawsuit?

On Monday, Biogen Inc. (NASDAQ:BIIB) shares edged higher 1% after Teva Pharmaceutical Industries Ltd (TLV:TEVA) settled the Vumerity lawsuit. The lawsuit claimed that Teva's proposed generic version of ...

Other symbols:TEVA
1 week ago - Invezz

Why Humana Is Suing Biogen

Biogen continues to deal with the aftermath of allegedly paying co-pays for some Medicare patients.

Other symbols:HUM
1 week ago - The Motley Fool